KEI Briefing Note 2020:2 The Federal Government’s Authority to Restrict or Eliminate Contractors’ Rights to Federally-Funded Inventions in “Exceptional Circumstances”
Access to Medicine
2020: USTR publishes a tone-deaf Special 301 Report, repeats old complaints
On April 29, 2020, the United States Trade Representative (USTR) published its annual Special 301 Report. A PDF copy of the report is available here. KEI has compiled copies of the Special 301 Report for every year since its inception… Continue Reading
KEI Comments on NIH Exclusive License to Kriya Therapeutics for Diabetes and Obesity Treatment
On Tuesday April 28, 2020, KEI submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: AAV Mediated Exendin-4 Gene Transfer to Salivary Glands To Protect Subjects From Diabetes or Obesity” (85… Continue Reading
KEI comments on the resolution WHA73: “Covid-19 Response” proposed by the European Union
On Friday, 24 April 2020, Knowledge Ecology International submitted comments on the resolution WHA73: “Covid-19 Response” proposed by the European Union (EU). The original zero draft text and the note verbale proposed by the European Union can be found here.… Continue Reading
Canada notifies WTO on Bill C-13 to facilitate compulsory licensing in the COVID-19 response
Under the notification of laws and regulations obligations of Article 63.2 of the World Trade Organization’s (WTO) TRIPS Agreement, on 23 April 2020, Canada sent a notification (IP/N/1/CAN/30) to the WTO in relation to “Bill C-13 An Act respecting certain… Continue Reading
KEI Research Note 2020:1 Government funding related to the cobas Liat Analyzer PCR testing device
KEI Research Note 2020:1 Government funding related to the cobas Liat Analyzer PCR testing device. Luis Gil Abinader, April 22, 2020. Introduction Polymerase chain reaction (PCR) testing technique Automatization of the PCR testing technique SARS-Cov-2 emergency use authorizations for PCR… Continue Reading
KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech
On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of… Continue Reading
KEI Comments Regarding NIH Exclusive License for Adoptive Cell Therapy to Lyell Immunopharma
On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” to Lyell Immunopharma, Inc. (85 FR… Continue Reading
European Union Draft Resolution on COVID-19 for WHA73
On Wednesday, 15 April 2020, the European Union submitted a zero draft of a resolution for the World Health Assembly entitled WHA73: “Covid-19 Response”; this text was accompanied by a note verbale. The note verbale stated the following: We understand… Continue Reading
KEI letter to Brazil Congress, regarding compulsory licensing bill
Brazil-CL-Pandemics-KEI-10April2020 April 10, 2020 Members of the Brazil Congress It is our understanding that some large drug companies have raised objections to a new compulsory licensing authority for Brazil relating to pandemics. I would like to address the several objections… Continue Reading